Could common diabetes drugs reverse early memory loss?
NCT ID NCT05313529
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether three diabetes medications—liraglutide, empagliflozin, and linagliptin—can help reverse mild cognitive impairment (early memory and thinking problems) in people with type 2 diabetes. About 396 participants will take one of the drugs for 48 weeks, with an additional 28-week follow-up. The goal is to see if these drugs can improve memory and daily function enough to no longer meet the criteria for mild cognitive impairment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
liraglutide, empagliflozin, and linagliptin (diabetes medications)
What this could lead to
If successful, this could point toward a way to treat mild cognitive impairment in people with type 2 diabetes using existing diabetes drugs.
What could go wrong
This is an early-stage, open-label trial with no placebo group, so results may be less reliable. The cognitive benefits may be small or not last long-term.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MILD COGNITIVE IMPAIRMENT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Department of Endocrinology, Changzhou No.2 People's Hospital, the Affiliated Hospital of Nanjing Medical University
Changzhou, Jiangsu, 213000, China
-
Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University
Nanjing, Jiangsu, 210000, China
-
Department of Endocrinology, The Affiliated Wuxi People's Hospital of Nanjing Medical University
Wuxi, Jiangsu, 214000, China
-
Department of Endocrinology, the Affiliated Drum Tower Hospital of Nanjing University Medical School
Nanjing, Jiangsu, 210008, China
-
Department of Endocrinology, the Affiliated Jiangning Hospital of Nanjing Medical University
Nanjing, Jiangsu, 211100, China